DNB Asset Management AS Purchases 7,794 Shares of Icon Plc $ICLR

DNB Asset Management AS increased its position in Icon Plc (NASDAQ:ICLR) by 31.4% in the 4th quarter, Holdings Channel reports. The firm owned 32,589 shares of the medical research company’s stock after buying an additional 7,794 shares during the quarter. DNB Asset Management AS’s holdings in Icon were worth $5,938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of ICLR. Toth Financial Advisory Corp bought a new position in Icon in the fourth quarter worth $27,000. Ameriflex Group Inc. bought a new position in Icon in the third quarter worth $33,000. Wilmington Savings Fund Society FSB lifted its position in Icon by 153.4% in the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after purchasing an additional 201 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in Icon in the third quarter worth $63,000. Finally, Johnson Financial Group Inc. bought a new position in Icon in the third quarter worth $71,000. 95.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

ICLR has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on Icon from $175.00 to $120.00 and set a “neutral” rating for the company in a report on Monday. Leerink Partners set a $125.00 price objective on Icon in a report on Monday, May 4th. BMO Capital Markets raised Icon from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $100.00 to $130.00 in a report on Thursday, March 26th. Citigroup cut their price objective on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. Finally, Robert W. Baird set a $119.00 price objective on Icon in a report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Icon presently has an average rating of “Hold” and a consensus target price of $145.67.

Icon Stock Down 2.2%

Shares of NASDAQ ICLR opened at $113.78 on Tuesday. The stock has a market cap of $9.19 billion, a PE ratio of 15.40, a PEG ratio of 3.04 and a beta of 1.23. The business has a fifty day moving average of $109.79 and a two-hundred day moving average of $144.11. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.